STOCK MARKETS

Science Corp valuation hits $3.5B on retina chip funding - Bloomberg

By Investing.com2 min readInvesting.com
Science Corp valuation hits $3.5B on retina chip funding - Bloomberg

Science Corp, the developer of a retinal chip that restores partial vision to people with age-related blindness, reached a $3.5 billion valuation following a recent fundraising round, according to reporting from Bloomberg. The company raised $400 million to advance implants treating blindness and develop neural devices that connect to the brain using engineered cells. Investors in the round include Khosla Ventures, Tenet Healthcare Corp, and the Ackman Oxman Institute, a brain research center established this year by hedge fund billionaire Bill Ackman and his wife Neri Oxman.

Science Corp’s Prima device, approved in Europe earlier this year, is the first treatment that restores some vision to people with age-related macular degeneration, the most common form of vision loss in older people. The device is a chip that sits in the eye and works with a companion pair of glasses.

The company has implanted the commercial version of its retina chip in two patients in Germany and has dozens more being scheduled. Patients are now receiving the Prima implant in Germany, and it will be available soon in Italy, France and the UK, a company spokesperson said to Bloomberg. Science Corp plans to make the device available for cash-paying patients at Moorfields Private Eye Hospital in London but declined to disclose the cost.

Science Corp has submitted the Prima device to the U.S. Food and Drug Administration for approval. Chief Executive Officer Max Hodak told Bloomberg in an interview that he expects it will be commercially available in the U.S. in the first half of next year. Hodak was also a cofounder and former president of Neuralink, the brain implant company backed by Elon Musk.

The company is developing another type of implant that plugs directly into the brain using engineered neurons. The company has chosen the first disease it hopes to treat with this experimental implant but has not announced it, Hodak said. The device has been tested in animals, and Science Corp hopes to test it in humans in the next 16 months.